Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$7.39 USD
-0.07 (-0.94%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $7.29 -0.10 (-1.35%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TPST 7.39 -0.07(-0.94%)
Will TPST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TPST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TPST
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
TPST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TPST
Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial
Tempest Therapeutics Secures $4.1M in Direct Offering
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreement | TPST Stock News
Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%
Tempest prices 739,000 shares at $6.25 in registered direct offering